Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Design Therapeutics Inc (DSGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: DSGN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.33
1 Year Target Price $7.33
| 0 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -75.14% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 222.53M USD | Price to earnings Ratio - | 1Y Target Price 7.33 |
Price to earnings Ratio - | 1Y Target Price 7.33 | ||
Volume (30-day avg) 3 | Beta 1.62 | 52 Weeks Range 2.60 - 7.77 | Updated Date 07/13/2025 |
52 Weeks Range 2.60 - 7.77 | Updated Date 07/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.99 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -16.56% | Return on Equity (TTM) -22.59% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -4999783 | Price to Sales(TTM) 22642.01 |
Enterprise Value -4999783 | Price to Sales(TTM) 22642.01 | ||
Enterprise Value to Revenue 11004.35 | Enterprise Value to EBITDA -0.84 | Shares Outstanding 56768700 | Shares Floating 25535687 |
Shares Outstanding 56768700 | Shares Floating 25535687 | ||
Percent Insiders 36.09 | Percent Institutions 61.09 |
Upturn AI SWOT
Design Therapeutics Inc
Company Overview
History and Background
Design Therapeutics, Inc. was founded in 2017. The company is focused on developing treatments for diseases caused by inherited nucleotide repeats, using its GeneTAC platform to target the underlying cause of disease. They are still a clinical stage company and have not yet brought a drug to market.
Core Business Areas
- GeneTAC Molecular Tapes: Developing GeneTAC molecular tapes to address the underlying cause of nucleotide repeat expansion diseases.
- Preclinical Development: Conducting preclinical studies to advance pipeline candidates towards clinical trials. Focus on Friedreich ataxia (FA) and Myotonic Dystrophy Type 1 (DM1).
Leadership and Structure
The leadership team includes key executives in research and development, finance, and operations. The organizational structure is built around the GeneTAC platform and the development of therapeutics for repeat expansion disorders.
Top Products and Market Share
Key Offerings
- DT-101 (Friedreich Ataxia): DT-101 is Design Therapeutics' lead clinical candidate for Friedreich Ataxia (FA). This molecule is designed to reduce the expression of frataxin (FXN) gene in people with FA. The molecule is currently in Phase 1 clinical trials and is unapproved by the FDA. Competitors are Reata Pharmaceuticals (acquired by Biogen - BIIB) which has an approved drug called Skyclarys.
- DM1 Program: The DM1 (Myotonic Dystrophy Type 1) program is in preclinical development. It aims to reduce toxic RNA levels and address the underlying cause of DM1. There is no estimated market share or revenue from this product since it is in preclinical development and not approved by the FDA. Major competitors include Avidity Biosciences (RNA), which has an approved drug for DM1.
Market Dynamics
Industry Overview
The industry Design Therapeutics operates in is the biotechnology sector, specifically focused on genetic medicines and RNA therapeutics. The industry is competitive, with many companies developing novel approaches to treat genetic disorders.
Positioning
Design Therapeutics is positioned as a leader in developing treatments for nucleotide repeat expansion diseases using its proprietary GeneTAC platform. Their competitive advantage lies in their ability to target the root cause of these diseases.
Total Addressable Market (TAM)
The total addressable market for repeat expansion disorders is substantial, estimated to be billions of dollars. Design Therapeutics is positioned to capture a significant portion of this market with successful development and commercialization of its therapies.
Upturn SWOT Analysis
Strengths
- Proprietary GeneTAC platform
- Strong focus on nucleotide repeat expansion diseases
- Experienced leadership team
- Lead candidate in clinical trials
Weaknesses
- Early-stage company with no approved products
- High reliance on research and development success
- Cash burn rate due to R&D expenses
- Susceptible to clinical trial failures
Opportunities
- Expansion of GeneTAC platform to other repeat expansion diseases
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results leading to regulatory approval
- Growing demand for genetic therapies
Threats
- Clinical trial failures
- Competition from other companies developing genetic therapies
- Regulatory hurdles and approval delays
- Patent disputes
- Market volatility and funding risk
Competitors and Market Share
Key Competitors
- BIIB
- RNA
Competitive Landscape
Design Therapeutics competes with other companies developing treatments for repeat expansion disorders. Its competitive advantage lies in its GeneTAC platform, but it faces competition from companies with more advanced clinical programs and approved drugs.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by R&D progress and corporate partnerships.
Future Projections: Future growth is dependent on the success of clinical trials and potential regulatory approvals. Analyst estimates vary widely due to the uncertainty inherent in drug development.
Recent Initiatives: Recent initiatives include advancing DT-101 through clinical trials and expanding the preclinical pipeline.
Summary
Design Therapeutics is a clinical-stage company focused on developing genetic medicines for repeat expansion disorders, and its GeneTAC platform offers a novel approach to target the underlying cause of disease. While it has no approved products and depends on R&D, the company is focused on advancing DT-101 and expanding its pipeline. Clinical trial successes and strategic partnerships will be key to its long-term growth and potential market leadership. Market Volatility and funding are key items to look out for.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Design Therapeutics Investor Relations
- SEC Filings
- Market Research Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered as investment advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Design Therapeutics Inc
Exchange NASDAQ | Headquaters Carlsbad, CA, United States | ||
IPO Launch date 2021-03-26 | Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson Mr. Pratik Shah Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 56 | Website https://www.designtx.com |
Full time employees 56 | Website https://www.designtx.com | ||
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.